I periodically publish biotech & pharma analysis for a wide audience of investors on SeekingAlpha.
In addition to my publicly available research, I provide dedicated biotech investors with uncommon insights via my subscription service, Second-Level Investing, or SLI for short. If you value an independent, critical voice to help you navigate the high-risk / high-reward world of biotech investments, please consider supporting my work by way of an SLI membership. The below image includes a link to the service:
Second-Level Investing is hosted on the SeekingAlpha Marketplace platform, which provides members with secure access & privacy, a transparent billing policy, and a bespoke chat function. As an added benefit, SLI members also have access to all of my archived SeekingAlpha articles, including several articles otherwise reserved for “PRO+” subscribers (a service tailored to institutional investors).
The core value proposition of SLI is the combination of in-depth due diligence & equity research, interviews with industry executives, academic researchers and other subject matter experts, and finally a regular ‘biotech digest’ known as Food For Thought. Last but not least, I maintain an actively managed, highly concentrated & selective model portfolio which comprises a limited number of biotech stocks which I believe have genuine potential to create significant value in the medium term.